Evidence map›Paper›PMID 38792190›Full record

ArticleMolecules (Basel, Switzerland)2024

Discovery and Synthesis of Hydroxy-l-Proline Blockers of the Neutral Amino Acid Transporters SLC1A4 (ASCT1) and SLC1A5 (ASCT2).

Brent R Lyda, Gregory P Leary, Jill Farnsworth, Benjamin Seaver, Derek Silvius, Michael P Kavanaugh, C Sean Esslinger, Nicholas R Natale

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Brent R LydaDivision of Biological Sciences, University of Montana, 32 Campus Dr., Missoula, MT 59812, USA.
Gregory P LearyDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, 32 Campus Dr., Missoula, MT 59812, USA.
Jill FarnsworthDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, 32 Campus Dr., Missoula, MT 59812, USA.
Benjamin SeaverDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, 32 Campus Dr., Missoula, MT 59812, USA.
Derek SilviusDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, 32 Campus Dr., Missoula, MT 59812, USA.
Michael P KavanaughDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, 32 Campus Dr., Missoula, MT 59812, USA.
C Sean EsslingerDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, 32 Campus Dr., Missoula, MT 59812, USA.
Nicholas R NataleDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, 32 Campus Dr., Missoula, MT 59812, USA.ORCID 0000-0003-4595-5006

Funding

Homeostatic control of the NMDA receptor co-agonist D-serine by SLC1A4R01MH110646 · NIMH · MC LAUGHLIN RESEARCH INSTITUTE · PI GUNN, TERESA M · 2018 to 2022
$2.0M
Glutamine Transport Pharmacology in the CNSR01NS045704 · NINDS · UNIVERSITY OF MONTANA · PI ESSLINGER, CHRISTOPHER SEAN · 2004 to 2007
$1.1M
NIMH NIH HHS R01 MH110646NINDS NIH HHS R01 NS045704
6 · The paper itself

Abstract

As a conformationally restricted amino acid, hydroxy-l-proline is a versatile scaffold for the synthesis of diverse multi-functionalized pyrrolidines for probing the ligand binding sites of biological targets. With the goal to develop new inhibitors of the widely expressed amino acid transporters SLC1A4 and SLC1A5 (also known as ASCT1 and ASCT2), we synthesized and functionally screened synthetic hydroxy-l-proline derivatives using electrophysiological and radiolabeled uptake methods against amino acid transporters from the SLC1, SLC7, and SLC38 solute carrier families. We have discovered a novel class of alkoxy hydroxy-pyrrolidine carboxylic acids (AHPCs) that act as selective high-affinity inhibitors of the SLC1 family neutral amino acid transporters SLC1A4 and SLC1A5. AHPCs were computationally docked into a homology model and assessed with respect to predicted molecular orientation and functional activity. The series of hydroxyproline analogs identified here represent promising new agents to pharmacologically modulate SLC1A4 and SLC1A5 amino acid exchangers which are implicated in numerous pathophysiological processes such as cancer and neurological diseases.

Indexed as

Amino Acid Transport System ASCDrug DiscoveryMinor Histocompatibility AntigensAnimalsHEK293 CellsHumansMolecular Docking SimulationProlinePyrrolidinesStructure-Activity RelationshipAmino Acid Transport System ASCMinor Histocompatibility AntigensProlinePyrrolidinesSLC1A4 protein, humanSLC1A5 protein, humanalkoxy hydroxy-pyrrolidine carboxylic acids (AHPCs)computational homology modelelectrophysiologySLC1A4 (ASCT1)SLC1A5 (ASCT2)solute carrier superfamily (SLC)

Identifiers

PMID38792190
PMCPMC11123841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.